NSE: DRREDDY · 22 October 2026
- Dr. Reddy's Laboratories shares edged lower during the session, trading down by 0.44% to close at ₹1,239.00 compared to its previous close of ₹1,244.50. The stock moved within a daily range of ₹1,212.70 and ₹1,250.70 after opening slightly lower at ₹1,236.00.
- The United States Food and Drug Administration completed a pre-approval inspection at the company's FTO-9 manufacturing facility in Visakhapatnam, Andhra Pradesh, between October 8 and October 9, 2026. The inspection resulted in the issuance of a Form 483 containing three observations. The company stated it will address these observations within the stipulated timeline.
- Trading volume was 1.29 times the 20-day average daily volume.
Why is Dr. Reddy S Laboratories share price falling on 22 October 2026?
Dr. Reddy's Laboratories shares edged lower during the session, trading down by 0.44% to close at ₹1,239.00 compared to its previous close of ₹1,244.50. The stock moved within a daily range of ₹1,212.70 and ₹1,250.70 after opening slightly lower at ₹1,236.00.
In broader market context, the stock's minor pullback occurred alongside a sharper decline in the benchmark Nifty index, which fell 0.88%, while the sectoral Nifty Pharma index remained relatively resilient with a minor loss of 0.07%. Over the preceding trading days, the stock had posted gains of 0.16% and 0.93% over the prior two sessions, and a 5-day return of 1.89%, indicating the day's move followed a period of modest short-term strength.
Company-specific news flow includes the recent regulatory update from October 21, 2026, where the company announced that the DCGI approved Zytorvi (toripalimab) for advanced esophageal squamous cell carcinoma in India. Additionally, investors are monitoring upcoming quarterly financial results scheduled for release on October 23, 2026, though no single catalyst was directly linked to today's minor price adjustment.
28.05 lakh shares traded by 22 October 2026 · 03:30 PM IST. This compares with a 20-day average daily volume of 21.67 lakh shares (1.29 times). The five-day average daily volume was 13.03 lakh shares. Separately, the NSE report for 22 October 2026 showed 14.89 lakh shares delivered, representing 53.08% of that day’s traded volume. The same report recorded 59,886 trades.
The 0.44% decline appears consistent with minor profit-taking following recent positive short-term returns, occurring alongside a broader market dip led by the Nifty index while trading volume remained active above average levels.
Latest Company Developments
The United States Food and Drug Administration completed a pre-approval inspection at the company's FTO-9 manufacturing facility in Visakhapatnam, Andhra Pradesh, between October 8 and October 9, 2026. The inspection resulted in the issuance of a Form 483 containing three observations. The company stated it will address these observations within the stipulated timeline.
Timely resolution of regulatory observations is crucial for securing final product approvals tied to this manufacturing unit.
The company formally notified the stock exchanges that it will convene a board meeting to approve its standalone and consolidated financial results for the quarter and six months ended September 30, 2026. An earnings call with management is scheduled for October 23, 2026, at 19:30 PM IST to discuss the operational performance.
Provides investors with the official timeline to assess quarterly revenue growth, profit margins, and segment performance against expectations.
a press release dated October 21, 2026, titled "Dr. Reddy s Receives DCGI Approval for Zytorvi® (toripalimab) in Advanced Esophageal Squamous Cell Carcinoma, Its Second Approved Indication in India.".
a press release dated October 07, 2026, titled "Intimation of Earnings call".
imposition of penalty to Dr. Reddy s Laboratories, Inc. ( DRL Inc ), a step-down wholly owned subsidiary of the Company.
Ownership & Transaction Activity
Mutual Fund Holdings
Mutual funds held 14.14% on 30 September 2026. This compares with 13.16% on 30 June 2026, a change of +0.98 percentage points.
The filing reported 40 MF/UTI holders.
What to Watch Next
- Release of Q2 FY27 financial results and management commentary on October 23, 2026
- Updates on the regulatory response to the USFDA Form 483 observations at the Visakhapatnam facility
- Commercial progress and market uptake following the recent DCGI approval of Zytorvi in India
- Delivery volume trends and cash market participation relative to the 20-day average volume
Other Dated Coverage
- Dr. Reddy S Laboratories Share Price Today: Why DRREDDY Is Rising 0.22% | 21 October 2026 — 21 October 2026
- Dr. Reddy's Laboratories in Focus After USFDA Issues Form 483 | 15 October 2026 — 15 October 2026
- Dr. Reddy S Laboratories Share Price Today: Why DRREDDY Is Rising 2.71% | 13 October 2026 — 13 October 2026
More Dr. Reddy S Laboratories news and dated analysis →
Frequently Asked Questions
What is the latest Dr. Reddy S Laboratories company news?
The United States Food and Drug Administration completed a pre-approval inspection at the company's FTO-9 manufacturing facility in Visakhapatnam, Andhra Pradesh, between October 8 and October 9, 2026. The inspection resulted in the issuance of a Form 483 containing three observations. The company stated it will address these observations within the stipulated timeline.
How strong was Dr. Reddy S Laboratories’s trading volume?
28.05 lakh shares traded, 1.29 times the 20-day average daily volume. The price and volume data are dated 22 October 2026 · 03:30 PM IST.
Do the mutual-fund figures show buying today?
They show holdings on 30 September 2026. Quarterly holdings do not identify purchases made on the article date.
Research & analysis: WittyTrades Research Desk
Reviewed by: Mohanish Sanghavi — SEBI Registered Research Analyst
Disclaimer: Investments in securities markets are subject to market risks. Registration with SEBI and NISM certification do not guarantee performance or returns. This article is for information and education, not personalised investment advice or a recommendation to buy, sell or hold.